A innovative monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – represents significant opportunity for the management of severe immune disease (TRALI). Created by Bio-X, Pritoxaximab operates by https://bookmarklinking.com/story178665/pritoxaximab-a-deep-dive-into-dxx00601-s-potential